N-(3-Acyloxy-2-Benzylpropyl)-N′-Dihydroxytetrahydrobenzazepine and Tetrahydroisoquinoline Thiourea Analogues as Vanilloid Receptor Ligands
摘要:
The vanilloid receptor represents a promising target for drug development. Building on our previous strategies which have generated potent agonists for VR1, we now describe a series of novel N-(3-acyloxy-2-benzylpropyl)-N'-dihydroxytetrahydro-benzazepine and tetrahydroisoquinoline thiourea analogues, several of which are potent VRI antagonists. We report here the rationale for the design, the synthesis, and the in vitro characterization of activity in assays for [H-3]resiniferatoxin binding and Ca-45 influx using heterologously expressed rat VRI. (C) 2001 Elsevier Science Ltd. All rights reserved.
N-(3-Acyloxy-2-Benzylpropyl)-N′-Dihydroxytetrahydrobenzazepine and Tetrahydroisoquinoline Thiourea Analogues as Vanilloid Receptor Ligands
摘要:
The vanilloid receptor represents a promising target for drug development. Building on our previous strategies which have generated potent agonists for VR1, we now describe a series of novel N-(3-acyloxy-2-benzylpropyl)-N'-dihydroxytetrahydro-benzazepine and tetrahydroisoquinoline thiourea analogues, several of which are potent VRI antagonists. We report here the rationale for the design, the synthesis, and the in vitro characterization of activity in assays for [H-3]resiniferatoxin binding and Ca-45 influx using heterologously expressed rat VRI. (C) 2001 Elsevier Science Ltd. All rights reserved.
[EN] PHARMACOLOGICAL TREATMENTS FOR SLEEP DISORDERS<br/>[FR] TRAITEMENTS PHARMACOLOGIQUES CONTRE DES TROUBLES DU SOMMEIL
申请人:UNIV ILLINOIS
公开号:WO2007047575A2
公开(公告)日:2007-04-26
[EN] This invention is directed to methods for preventing or ameliorating sleep-related breathing disorders. The method comprises administration to a patient in need thereof an effective dose of one or a combination of vanilloid receptor ligands. The vanilloid receptor ligand or combination of vanilloid receptor ligands can be administered in conjunction with one or more serotonin receptor agonists, one or more cannabimimetic agents, one or more serotonin reuptake inhibitors, one or more noradrenalin reuptake inhibitors, a combination of reuptake inhibitors, one or more inhibitors of vanilloid synthesis or vanilloid release, or any combination of the foregoing. [FR] L'invention concerne des méthodes pour prévenir ou améliorer des troubles de la respiration associés au sommeil. La méthode consiste à administrer à un patient une dose efficace d'un ligand ou d'une combinaison de ligands du récepteur vanilloïde. Le ligand ou la combinaison de ligands du récepteur vanilloïde peuvent être administrés en conjonction avec un ou plusieurs agonistes du récepteur de sérotonine, un ou plusieurs agents cannabimimétiques, un ou plusieurs inhibiteurs de recaptage de sérotonine, un ou plusieurs inhibiteurs de recaptage de noradrénaline, une combinaison d'inhibiteurs de recaptage, un ou plusieurs inhibiteurs de synthèse ou de libération de vanilloïde ou une combinaison quelconque de ces substances.
N-(3-Acyloxy-2-Benzylpropyl)-N′-Dihydroxytetrahydrobenzazepine and Tetrahydroisoquinoline Thiourea Analogues as Vanilloid Receptor Ligands
作者:Jeewoo Lee、Jiyoun Lee、Tamas Szabo、Adamar F Gonzalez、Jacqueline D Welter、Peter M Blumberg
DOI:10.1016/s0968-0896(01)00068-2
日期:2001.7
The vanilloid receptor represents a promising target for drug development. Building on our previous strategies which have generated potent agonists for VR1, we now describe a series of novel N-(3-acyloxy-2-benzylpropyl)-N'-dihydroxytetrahydro-benzazepine and tetrahydroisoquinoline thiourea analogues, several of which are potent VRI antagonists. We report here the rationale for the design, the synthesis, and the in vitro characterization of activity in assays for [H-3]resiniferatoxin binding and Ca-45 influx using heterologously expressed rat VRI. (C) 2001 Elsevier Science Ltd. All rights reserved.